Introduktion
Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Patrick G Enright. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.
Gennemsnitlig handelsrentabilitet
Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.
Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.
Opdateringsfrekvens: Dagligt
Virksomheder med rapporterede insider-stillinger
SEC-registreringen viser, at Patrick G Enright har rapporteret besiddelser eller handler i følgende virksomheder:
Sikkerhed | Titel | Senest indberettede beholdninger |
---|---|---|
US:JAZZ / Jazz Pharmaceuticals plc | Director | 26.379 |
US:VERA / Vera Therapeutics, Inc. | Director | 3.596.593 |
Director | 1.710.589 | |
Director | 774.530 | |
US:LXEO / Lexeo Therapeutics, Inc. | 10% Owner | 2.567.100 |
US:APTX / Aptinyx Inc. | Director | 40.000 |
US:SRRA / Sierra Oncology Inc | 10% Owner | 8.015 |
US:INZY / Inozyme Pharma, Inc. | 10% Owner | 4.174.379 |
US:RPID / Rapid Micro Biosystems, Inc. | 10% Owner | 129.032 |
US:TALS / Talaris Therapeutics Inc | 10% Owner | 0 |
US:EAR / Eargo, Inc. | 10% Owner | 5.012 |
US:ETNB / 89bio, Inc. | 10% Owner | 891 |
Director | 0 | |
US:MTEM / Molecular Templates, Inc. | 10% Owner | 0 |
US:VERO / Venus Concept Inc. | 10% Owner | 7.332.238 |
US:AXNX / Axonics, Inc. | 10% Owner | 0 |
US:TCDA / Tricida Inc | 10% Owner | 0 |
US:COLL / Collegium Pharmaceutical, Inc. | 10% Owner | 45.620 |
US:KALA / KALA BIO, Inc. | 10% Owner | 0 |
US:CORT / Corcept Therapeutics Incorporated | Director | 114.675 |
US:ESPR / Esperion Therapeutics, Inc. | Director | 8.000 |
Sådan fortolkes diagrammerne
Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Patrick G Enright. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.
I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.
Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.
Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.
Insiderkøb COLL / Collegium Pharmaceutical, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i COLL / Collegium Pharmaceutical, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg COLL / Collegium Pharmaceutical, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i COLL / Collegium Pharmaceutical, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb CORT / Corcept Therapeutics Incorporated – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i COLL / Collegium Pharmaceutical, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg CORT / Corcept Therapeutics Incorporated – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i COLL / Collegium Pharmaceutical, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb ESPR / Esperion Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i COLL / Collegium Pharmaceutical, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ESPR / Esperion Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i COLL / Collegium Pharmaceutical, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb ETNB / 89bio, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i COLL / Collegium Pharmaceutical, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ETNB / 89bio, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i COLL / Collegium Pharmaceutical, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb KALA / KALA BIO, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i COLL / Collegium Pharmaceutical, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2017-07-25 | KALA | Longitude Capital Partners II, LLC | 215.000 | 15,0000 | 4.300 | 750,0000 | 3.225.000 | 51 | 1326.5 | 2.478.950 | 76,87 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg KALA / KALA BIO, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i COLL / Collegium Pharmaceutical, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb LXEO / Lexeo Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i COLL / Collegium Pharmaceutical, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2023-11-07 | LXEO | Longitude Capital Partners IV, LLC | 454.545 | 11,0000 | 454.545 | 11,0000 | 4.999.995 | 219 | 18.7600 | 3.527.269 | 70,55 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg LXEO / Lexeo Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i COLL / Collegium Pharmaceutical, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb RPID / Rapid Micro Biosystems, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i COLL / Collegium Pharmaceutical, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2021-07-19 | RPID | Longitude Capital Partners II, LLC | 150.000 | 20,0000 | 150.000 | 20,0000 | 3.000.000 | 17 | 24.8 | 720.000 | 24,00 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg RPID / Rapid Micro Biosystems, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i COLL / Collegium Pharmaceutical, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb TRML / Tourmaline Bio, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i COLL / Collegium Pharmaceutical, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2021-05-11 | TALS | Longitude Capital Partners III, LLC | 235.000 | 17,0000 | 235.000 | 17,0000 | 3.995.000 | 27 | 18.61 | 378.350 | 9,47 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg TRML / Tourmaline Bio, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i COLL / Collegium Pharmaceutical, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb VERA / Vera Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i COLL / Collegium Pharmaceutical, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg VERA / Vera Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i COLL / Collegium Pharmaceutical, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb VERO / Venus Concept Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i COLL / Collegium Pharmaceutical, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg VERO / Venus Concept Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i COLL / Collegium Pharmaceutical, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderhandelshistorie
Denne tabel viser den komplette liste over insiderhandler foretaget af Patrick G Enright som oplyst til Securities Exchange Commission (SEC).
Fil dato | Transdato | Form | Ticker | Sikkerhed | Kode | Aktier | Resterende aktier | Procent Lave om |
Del Pris |
Tran Værdi |
Tilbage Værdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
F - Taxes | -1.805 | 26.379 | -6,40 | 111,25 | -200.805 | 2.934.640 | |
2025-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 3.507 | 28.184 | 14,21 | ||||
2025-06-25 |
|
4 | VERA |
Vera Therapeutics, Inc.
Class A Common Stock |
P - Purchase | 27.071 | 3.596.593 | 0,76 | 22,35 | 605.083 | 80.389.968 | |
2025-06-25 |
|
4 | VERA |
Vera Therapeutics, Inc.
Class A Common Stock |
P - Purchase | 13.536 | 1.797.619 | 0,76 | 22,35 | 302.553 | 40.179.841 | |
2025-06-25 |
|
4 | VERA |
Vera Therapeutics, Inc.
Class A Common Stock |
P - Purchase | 139.595 | 3.569.522 | 4,07 | 20,87 | 2.913.110 | 74.489.856 | |
2025-06-25 |
|
4 | VERA |
Vera Therapeutics, Inc.
Class A Common Stock |
P - Purchase | 69.798 | 1.784.083 | 4,07 | 20,87 | 1.456.566 | 37.230.779 | |
2024-09-27 |
|
4 | BIOA |
BioAge Labs, Inc.
Common Stock |
P - Purchase | 400.000 | 1.710.589 | 30,52 | 18,00 | 7.200.000 | 30.790.602 | |
2024-09-27 |
|
4 | BIOA |
BioAge Labs, Inc.
Common Stock |
C - Conversion | 1.310.589 | 1.310.589 | |||||
2024-09-16 |
|
4 | ZBIO |
Zenas BioPharma, Inc.
Common Stock |
P - Purchase | 440.000 | 774.530 | 131,53 | 17,00 | 7.480.000 | 13.167.010 | |
2024-09-16 |
|
4 | ZBIO |
Zenas BioPharma, Inc.
Common Stock |
C - Conversion | 334.530 | 334.530 | |||||
2024-09-16 |
|
4 | ZBIO |
Zenas BioPharma, Inc.
Common Stock |
C - Conversion | 1.003.592 | 1.727.404 | 138,65 | ||||
2024-09-16 |
|
4 | ZBIO |
Zenas BioPharma, Inc.
Common Stock |
C - Conversion | 723.812 | 723.812 | |||||
2024-08-06 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 3.731 | 24.677 | 17,81 | ||||
2023-11-09 |
|
4 | LXEO |
Lexeo Therapeutics, Inc.
Common Stock |
P - Purchase | 454.545 | 2.567.100 | 21,52 | 11,00 | 4.999.995 | 28.238.100 | |
2023-11-09 |
|
4 | LXEO |
Lexeo Therapeutics, Inc.
Common Stock |
C - Conversion | 319.126 | 2.112.555 | 17,79 | ||||
2023-11-09 |
|
4 | LXEO |
Lexeo Therapeutics, Inc.
Common Stock |
C - Conversion | 1.793.429 | 1.793.429 | |||||
2023-08-15 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1.241 | 20.946 | -5,59 | 138,16 | -171.455 | 2.893.868 | |
2023-08-15 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 3.075 | 22.187 | 16,09 | ||||
2023-02-08 |
|
4 | VERA |
Vera Therapeutics, Inc.
Class A Common Stock |
P - Purchase | 1.714.285 | 1.714.285 | 7,00 | 11.999.995 | 11.999.995 | ||
2022-11-25 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2.000 | 0 | -100,00 | 152,88 | -305.751 | ||
2022-11-25 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2.069 | 19.112 | -9,77 | 149,90 | -310.149 | 2.864.942 | |
2022-11-25 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2.905 | 21.181 | -12,06 | 149,18 | -433.364 | 3.159.752 | |
2022-08-09 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1.089 | 24.086 | -4,33 | 152,33 | -165.883 | 3.668.934 | |
2022-08-09 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 2.561 | 25.175 | 11,32 | ||||
2022-05-31 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 40.000 | 40.000 | |||||
2022-05-26 |
|
4 | VERA |
Vera Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 9.925 | 9.925 | |||||
2022-04-29 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
J - Other | 840 | 8.015 | 11,71 | ||||
2022-04-29 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
J - Other | 252 | 2.404 | 11,71 | ||||
2022-04-29 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
J - Other | 588 | 5.611 | 11,71 | ||||
2022-04-29 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
J - Other | 7.175 | 7.175 | |||||
2022-04-29 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
J - Other | 2.152 | 2.152 | |||||
2022-04-29 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
J - Other | 5.023 | 5.023 | |||||
2022-04-29 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
J - Other | -1.964.771 | 0 | -100,00 | ||||
2022-04-29 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
J - Other | -175.000 | 0 | -100,00 | ||||
2022-04-21 |
|
4 | INZY |
Inozyme Pharma, Inc.
Common Stock |
P - Purchase | 1.355.000 | 4.174.379 | 48,06 | 3,69 | 4.999.950 | 15.403.459 | |
2022-04-05 |
|
4 | VERA |
Vera Therapeutics, Inc.
Class A Common Stock |
P - Purchase | 333.333 | 3.429.927 | 10,76 | 15,00 | 4.999.995 | 51.448.905 | |
2022-02-02 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
P - Purchase | 175.000 | 175.000 | 27,00 | 4.725.000 | 4.725.000 | ||
2022-01-27 |
|
4 | SRRA |
Sierra Oncology, Inc.
Series B Warrants |
X - Other | -1.477.125 | 0 | -100,00 | 13,20 | -19.498.050 | ||
2022-01-27 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
X - Other | 487.451 | 1.964.771 | 33,00 | 13,20 | 6.434.353 | 25.934.977 | |
2021-08-20 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 2.000 | 2.000 | 137,75 | 275.500 | 275.500 | ||
2021-08-02 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 2.246 | 22.614 | 11,03 | ||||
2021-07-20 |
|
4 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Common Stock Warrant |
C - Conversion | 129.032 | 129.032 | |||||
2021-07-20 |
|
4 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Series B1 Warrant |
C - Conversion | -645.160 | 0 | -100,00 | ||||
2021-07-20 |
|
4 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Common Stock Warrant |
C - Conversion | 500.000 | 500.000 | |||||
2021-07-20 |
|
4 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Series A1 Warrant |
C - Conversion | -2.500.000 | 0 | -100,00 | ||||
2021-07-20 |
|
4 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Series C1 Preferred Stock |
C - Conversion | -2.291.665 | 0 | -100,00 | ||||
2021-07-20 |
|
4 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Series B1 Preferred Stock |
C - Conversion | -5.654.529 | 0 | -100,00 | ||||
2021-07-20 |
|
4 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Series A1 Preferred Stock |
C - Conversion | -8.774.007 | 0 | -100,00 | ||||
2021-07-20 |
|
4 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Class A Common Stock |
P - Purchase | 150.000 | 150.000 | 20,00 | 3.000.000 | 3.000.000 | ||
2021-07-20 |
|
4 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Class A Common Stock |
C - Conversion | 3.344.038 | 3.407.952 | 5.232,09 | ||||
2021-07-14 | 3 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Class A Common Stock |
63.914 | ||||||||
2021-06-01 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 40.000 | 40.000 | |||||
2021-05-18 |
|
4 | VERA |
Vera Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -2.187.504 | 0 | -100,00 | ||||
2021-05-18 |
|
4 | VERA |
Vera Therapeutics, Inc.
Class A Common Stock |
P - Purchase | 909.090 | 3.096.594 | 41,56 | 11,00 | 9.999.990 | 34.062.534 | |
2021-05-18 |
|
4 | VERA |
Vera Therapeutics, Inc.
Class A Common Stock |
C - Conversion | 2.187.504 | 2.187.504 | |||||
2021-05-17 |
|
4 | VERA |
Vera Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 9.925 | 9.925 | |||||
2021-05-11 |
|
4 | TALS |
Talaris Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -406.338 | 0 | -100,00 | ||||
2021-05-11 |
|
4 | TALS |
Talaris Therapeutics, Inc.
Series A-1 Preferred Stock |
C - Conversion | -1.271.027 | 0 | -100,00 | ||||
2021-05-11 |
|
4 | TALS |
Talaris Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -1.308.410 | 0 | -100,00 | ||||
2021-05-11 |
|
4 | TALS |
Talaris Therapeutics, Inc.
Common Stock |
P - Purchase | 235.000 | 3.220.775 | 7,87 | 17,00 | 3.995.000 | 54.753.175 | |
2021-05-11 |
|
4 | TALS |
Talaris Therapeutics, Inc.
Common Stock |
C - Conversion | 2.985.775 | 2.985.775 | |||||
2021-04-15 |
|
4 | EAR |
Eargo, Inc.
Common Stock |
J - Other | 5.012 | 5.012 | |||||
2021-04-15 |
|
4 | EAR |
Eargo, Inc.
Common Stock |
J - Other | X | -1.000.000 | 2.918.691 | -25,52 | |||
2021-01-05 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 8.149 | 8.149 | 2,22 | 18.123 | 18.123 | ||
2020-11-18 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
J - Other | 891 | 891 | |||||
2020-11-18 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
J - Other | 2.080 | 2.080 | |||||
2020-11-18 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
J - Other | 2.973 | 2.973 | |||||
2020-11-18 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
J - Other | -850.000 | 1.750.877 | -32,68 | ||||
2020-11-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -1.623 | 20.368 | -7,38 | 147,61 | -239.575 | 3.006.565 |
2020-11-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -5.083 | 21.991 | -18,77 | 147,00 | -747.217 | 3.232.747 |
2020-11-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -3.223 | 27.074 | -10,64 | 145,81 | -469.946 | 3.947.665 |
2020-11-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Phantom Stock |
M - Exercise | -9.929 | 0 | -100,00 | ||||
2020-11-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
M - Exercise | 9.929 | 30.297 | 48,75 | ||||
2020-10-22 |
|
4 | EAR |
Eargo, Inc.
Series E Preferred Stock |
C - Conversion | -3.685.358 | 0 | -100,00 | ||||
2020-10-22 |
|
4 | EAR |
Eargo, Inc.
Common Stock |
P - Purchase | 233.333 | 3.918.691 | 6,33 | 18,00 | 4.199.994 | 70.536.438 | |
2020-10-22 |
|
4 | EAR |
Eargo, Inc.
Common Stock |
C - Conversion | 3.685.358 | 3.685.358 | |||||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
D - Sale to Issuer | -15.398 | 0 | -100,00 | 17,39 | -267.771 | ||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
D - Sale to Issuer | -11.432 | 0 | -100,00 | 14,60 | -166.907 | ||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
D - Sale to Issuer | -7.500 | 0 | -100,00 | 1,71 | -12.825 | ||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
D - Sale to Issuer | -17.500 | 0 | -100,00 | 16,24 | -284.200 | ||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
D - Sale to Issuer | -19.755 | 0 | -100,00 | 19,10 | -377.320 | ||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
D - Sale to Issuer | -52.421 | 0 | -100,00 | 28,21 | -1.478.796 | ||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
D - Sale to Issuer | -65.849 | 0 | -100,00 | 34,36 | -2.262.572 | ||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
D - Sale to Issuer | -7.840 | 0 | -100,00 | 34,50 | -270.480 | ||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
U - Other | -91.697 | 0 | -100,00 | 34,50 | -3.163.546 | ||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
U - Other | -70.561 | 0 | -100,00 | 34,50 | -2.434.354 | ||
2020-10-02 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 8.379 | 8.379 | 2,16 | 18.124 | 18.124 | ||
2020-09-23 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
J - Other | 91.697 | 91.697 | |||||
2020-09-23 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
J - Other | -6.113.134 | 0 | -100,00 | ||||
2020-09-01 |
|
4 | MTEM |
Molecular Templates, Inc.
Common Stock |
S - Sale | -1.049 | 0 | -100,00 | 10,75 | -11.273 | ||
2020-09-01 |
|
4 | MTEM |
Molecular Templates, Inc.
Common Stock |
S - Sale | -2.447 | 0 | -100,00 | 10,75 | -26.296 | ||
2020-08-10 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-Qualified Stock Option (right to buy) |
A - Award | 6.765 | 6.765 | |||||
2020-08-10 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 2.705 | 20.368 | 15,31 | ||||
2020-07-28 |
|
4 | INZY |
Inozyme Pharma, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -1.398.600 | 0 | -100,00 | ||||
2020-07-28 |
|
4 | INZY |
Inozyme Pharma, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -15.000.000 | 0 | -100,00 | ||||
2020-07-28 |
|
4 | INZY |
Inozyme Pharma, Inc.
Common Stock |
P - Purchase | 625.000 | 2.819.379 | 28,48 | 16,00 | 10.000.000 | 45.110.064 | |
2020-07-28 |
|
4 | INZY |
Inozyme Pharma, Inc.
Common Stock |
C - Conversion | 187.154 | 2.194.379 | 9,32 | ||||
2020-07-28 |
|
4 | INZY |
Inozyme Pharma, Inc.
Common Stock |
C - Conversion | 2.007.225 | 2.007.225 | |||||
2020-07-14 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
P - Purchase | 109.090 | 2.600.877 | 4,38 | 27,50 | 2.999.975 | 71.524.118 | |
2020-07-02 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 5.436 | 5.436 | 2,68 | 14.552 | 14.552 | ||
2020-05-29 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 15.398 | 15.398 | |||||
2020-05-29 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
S - Sale | 7.840 | 78.401 | 11,11 | ||||
2020-05-28 |
|
4 | MTEM |
Molecular Templates, Inc.
Common Stock |
J - Other | 1.049 | 1.049 | |||||
2020-05-28 |
|
4 | MTEM |
Molecular Templates, Inc.
Common Stock |
J - Other | 2.447 | 2.447 | |||||
2020-05-28 |
|
4 | MTEM |
Molecular Templates, Inc.
Common Stock |
J - Other | 3.495 | 3.495 | |||||
2020-05-28 |
|
4 | MTEM |
Molecular Templates, Inc.
Common Stock |
J - Other | -1.000.000 | 3.199.035 | -23,81 | ||||
2020-05-22 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 40.000 | 40.000 | |||||
2020-04-02 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 8.573 | 8.573 | 1,36 | 11.625 | 11.625 | ||
2020-03-19 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 16.213 | 70.561 | 29,83 | 11,06 | 179.345 | 780.532 | |
2020-03-19 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 8.787 | 54.348 | 19,29 | 11,50 | 101.050 | 625.002 | |
2020-03-19 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 100.000 | 6.113.134 | 1,66 | 11,40 | 1.139.650 | 69.668.332 | |
2020-01-31 |
|
4 | SRRA |
Sierra Oncology, Inc.
Series A Convertible Voting Preferred Stock |
C - Conversion | -19.500 | 0 | -100,00 | ||||
2020-01-31 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
C - Conversion | 1.477.320 | 1.477.320 | |||||
2020-01-14 |
|
4 | APTX |
Aptinyx Inc.
Common Stock |
P - Purchase | 166.667 | 3.356.746 | 5,22 | 3,00 | 500.001 | 10.070.238 | |
2020-01-14 |
|
4 | APTX |
Aptinyx Inc.
Common Stock |
P - Purchase | 95.000 | 95.000 | 3,00 | 285.000 | 285.000 | ||
2020-01-03 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 5.427 | 5.427 | 2,14 | 11.625 | 11.625 | ||
2019-12-05 |
|
4/A | MTEM |
Molecular Templates, Inc.
Common Stock |
P - Purchase | 937.500 | 4.199.035 | 28,74 | 8,00 | 7.500.000 | 33.592.280 | |
2019-11-27 |
|
4 | MTEM |
Molecular Templates, Inc.
Common Stock |
P - Purchase | 937.000 | 4.198.535 | 28,73 | 8,00 | 7.496.000 | 33.588.280 | |
2019-11-13 |
|
4 | ETNB |
89bio, Inc.
Series A Preferred Stock |
C - Conversion | -11.916.667 | 0 | -100,00 | ||||
2019-11-13 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
C - Conversion | 1.916.787 | 2.491.787 | 333,35 | ||||
2019-11-13 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
P - Purchase | 575.000 | 575.000 | 16,00 | 9.200.000 | 9.200.000 | ||
2019-11-07 | 3 | VERO |
Venus Concept Inc.
Common Stock |
7.332.238 | ||||||||
2019-11-07 | 3 | VERO |
Venus Concept Inc.
Common Stock |
7.332.238 | ||||||||
2019-11-07 | 3 | VERO |
Venus Concept Inc.
Common Stock |
7.332.238 | ||||||||
2019-11-07 | 3 | VERO |
Venus Concept Inc.
Common Stock |
7.332.238 | ||||||||
2019-11-07 | 3 | VERO |
Venus Concept Inc.
Common Stock |
7.332.238 | ||||||||
2019-10-02 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 5.582 | 5.582 | 2,08 | 11.622 | 11.622 | ||
2019-09-19 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
A - Award | 12.500 | 45.561 | 37,81 | 22,34 | 279.216 | 1.017.710 | |
2019-08-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -726 | 17.663 | -3,95 | 135,65 | -98.481 | 2.395.967 | |
2019-08-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-Qualified Stock Option (right to buy) |
A - Award | 4.805 | 4.805 | |||||
2019-08-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 1.920 | 18.389 | 11,66 | ||||
2019-07-02 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 5.866 | 5.866 | 1,98 | 11.626 | 11.626 | ||
2019-05-28 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 11.432 | 11.432 | |||||
2019-05-28 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
A - Award | 6.442 | 33.061 | 24,20 | ||||
2019-05-17 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 40.000 | 40.000 | |||||
2019-04-02 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 4.793 | 4.793 | 2,42 | 11.623 | 11.623 | ||
2018-11-02 |
|
4 | AXNX |
Axonics Modulation Technologies, Inc.
Series C Preferred Stock |
C - Conversion | -2.000.000 | 0 | -100,00 | ||||
2018-11-02 |
|
4 | AXNX |
Axonics Modulation Technologies, Inc.
Common Stock |
P - Purchase | 533.333 | 2.933.333 | 22,22 | 15,00 | 7.999.995 | 43.999.995 | |
2018-11-02 |
|
4 | AXNX |
Axonics Modulation Technologies, Inc.
Common Stock |
C - Conversion | 2.400.000 | 2.400.000 | |||||
2018-09-25 |
|
4 | MTEM |
Molecular Templates, Inc.
Common Stock |
P - Purchase | 365.000 | 3.261.535 | 12,60 | 5,50 | 2.007.500 | 17.938.442 | |
2018-09-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | -3.415 | 0 | -100,00 | |||
2018-09-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | -3.415 | 0 | -100,00 | |||
2018-09-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | -3.300 | 0 | -100,00 | |||
2018-09-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -1.000 | 16.469 | -5,72 | 169,69 | -169.694 | 2.794.690 |
2018-09-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -7.086 | 17.469 | -28,86 | 168,86 | -1.196.565 | 2.949.873 |
2018-09-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -2.044 | 24.555 | -7,68 | 167,96 | -343.305 | 4.124.199 |
2018-09-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
M - Exercise | X | 3.300 | 26.599 | 14,16 | 135,44 | 446.952 | 3.602.569 |
2018-09-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
M - Exercise | X | 3.415 | 23.299 | 17,17 | 138,08 | 471.543 | 3.217.126 |
2018-09-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
M - Exercise | X | 3.415 | 19.884 | 20,74 | 143,66 | 490.599 | 2.856.535 |
2018-08-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1.365 | 16.469 | -7,65 | 175,13 | -239.057 | 2.884.272 | |
2018-08-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-Qualified Stock Option (right to buy) |
A - Award | 3.735 | 3.735 | |||||
2018-08-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 1.495 | 17.834 | 9,15 | ||||
2018-07-02 |
|
4 | TCDA |
Tricida, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -1.817.447 | 0 | -100,00 | ||||
2018-07-02 |
|
4 | TCDA |
Tricida, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -9.677.419 | 0 | -100,00 | ||||
2018-07-02 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
P - Purchase | 131.579 | 3.019.734 | 4,56 | 19,00 | 2.500.001 | 57.374.946 | |
2018-07-02 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
C - Conversion | 456.644 | 2.888.155 | 18,78 | ||||
2018-07-02 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
C - Conversion | 2.431.511 | 2.431.511 | |||||
2018-06-26 |
|
4 | APTX |
Aptinyx Inc.
Series B Convertible Preferred Stock |
C - Conversion | -21.946.301 | 0 | -100,00 | ||||
2018-06-26 |
|
4 | APTX |
Aptinyx Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -33.022.786 | 0 | -100,00 | ||||
2018-06-26 |
|
4 | APTX |
Aptinyx Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -28.895.188 | 0 | -100,00 | ||||
2018-06-26 |
|
4 | APTX |
Aptinyx Inc.
Common Stock |
P - Purchase | 150.000 | 3.190.079 | 4,93 | 16,00 | 2.400.000 | 51.041.264 | |
2018-06-26 |
|
4 | APTX |
Aptinyx Inc.
Common Stock |
C - Conversion | 795.553 | 3.040.079 | 35,44 | ||||
2018-06-26 |
|
4 | APTX |
Aptinyx Inc.
Common Stock |
C - Conversion | 1.197.076 | 2.244.526 | 114,28 | ||||
2018-06-26 |
|
4 | APTX |
Aptinyx Inc.
Common Stock |
C - Conversion | 1.047.450 | 1.047.450 | |||||
2018-05-24 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 7.500 | 7.500 | |||||
2018-05-24 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
A - Award | 3.750 | 26.619 | 16,40 | ||||
2018-02-26 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock |
P - Purchase | 15.593 | 22.869 | 214,31 | 32,00 | 498.976 | 731.808 | |
2017-12-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | -4.500 | 0 | -100,00 | |||
2017-12-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-employee director stock option |
M - Exercise | X | -4.500 | 0 | -100,00 | |||
2017-12-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -2.842 | 16.339 | -14,82 | 140,50 | -399.294 | 2.295.592 |
2017-12-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -5.358 | 19.181 | -21,83 | 139,56 | -747.771 | 2.676.931 |
2017-12-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -800 | 24.539 | -3,16 | 138,14 | -110.516 | 3.389.940 |
2017-12-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
M - Exercise | X | 4.500 | 25.339 | 21,59 | 81,76 | 367.920 | 2.071.717 |
2017-12-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
M - Exercise | X | 4.500 | 20.839 | 27,54 | 46,83 | 210.735 | 975.890 |
2017-12-12 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Common Stock |
S - Sale | -19.650 | 45.620 | -30,11 | 17,34 | -340.731 | 791.051 | |
2017-12-12 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Common Stock |
S - Sale | -980.350 | 2.276.222 | -30,10 | 17,34 | -16.999.269 | 39.469.689 | |
2017-11-21 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -352 | 1.365 | -20,50 | 133,19 | -46.883 | 181.804 |
2017-08-28 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -351 | 1.717 | -16,97 | 148,40 | -52.088 | 254.803 |
2017-08-14 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3 | 2.068 | -0,14 | 144,13 | -432 | 298.062 | |
2017-08-14 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -659 | 2.071 | -24,14 | 142,36 | -93.815 | 294.828 | |
2017-08-14 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-Qualified Stock Option (right to buy) |
A - Award | 3.415 | 3.415 | |||||
2017-08-14 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 1.365 | 2.730 | 100,00 | ||||
2017-08-07 | 3 | MTEM |
Molecular Templates, Inc.
Common Stock |
5.793.070 | ||||||||
2017-08-07 | 3 | MTEM |
Molecular Templates, Inc.
Common Stock |
5.793.070 | ||||||||
2017-08-07 | 3 | MTEM |
Molecular Templates, Inc.
Common Stock |
5.793.070 | ||||||||
2017-08-07 | 3 | MTEM |
Molecular Templates, Inc.
Common Stock |
5.793.070 | ||||||||
2017-08-07 | 3 | MTEM |
Molecular Templates, Inc.
Common Stock |
5.793.070 | ||||||||
2017-07-27 |
|
4 | KALA |
Kala Pharmaceuticals, Inc.
Series C Preferred Stock |
C - Conversion | -10.707.985 | 0 | -100,00 | ||||
2017-07-27 |
|
4 | KALA |
Kala Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 215.000 | 2.270.946 | 10,46 | 15,00 | 3.225.000 | 34.064.190 | |
2017-07-27 |
|
4 | KALA |
Kala Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 2.055.946 | 2.055.946 | |||||
2017-05-30 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 17.500 | 17.500 | |||||
2017-03-20 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -5.305 | 114.675 | -4,42 | 9,94 | -52.722 | 1.139.652 | |
2017-03-20 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -264.650 | 5.721.372 | -4,42 | 9,94 | -2.630.515 | 56.868.149 | |
2017-03-15 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -5.483 | 139.630 | -3,78 | 10,24 | -56.131 | 1.429.420 | |
2017-03-15 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -273.537 | 6.966.372 | -3,78 | 10,24 | -2.800.636 | 71.325.896 | |
2017-03-15 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -5.895 | 145.113 | -3,90 | 10,01 | -59.002 | 1.452.422 | |
2017-03-15 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -294.105 | 7.239.909 | -3,90 | 10,01 | -2.943.668 | 72.463.525 | |
2017-03-15 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -412 | 151.008 | -0,27 | 11,13 | -4.585 | 1.680.583 | |
2017-03-15 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -20.568 | 7.534.014 | -0,27 | 11,13 | -228.905 | 83.847.549 | |
2017-03-10 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -14.737 | 151.420 | -8,87 | 9,75 | -143.686 | 1.476.345 | |
2017-03-10 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -735.263 | 7.554.582 | -8,87 | 9,75 | -7.168.814 | 73.657.174 | |
2017-02-27 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -19.650 | 166.157 | -10,58 | 9,05 | -177.832 | 1.503.721 | |
2017-02-27 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -980.350 | 8.289.845 | -10,58 | 9,05 | -8.872.168 | 75.023.097 | |
2017-02-27 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -29.475 | 185.807 | -13,69 | 8,65 | -254.959 | 1.607.231 | |
2017-02-27 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -1.470.525 | 9.270.195 | -13,69 | 8,65 | -12.720.041 | 80.187.187 | |
2016-12-14 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
J - Other | 204.210 | 204.210 | |||||
2016-12-06 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -677 | 1.365 | -33,15 | 101,80 | -68.919 | 138.957 |
2016-12-01 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
J - Other | 7.276 | 7.276 | |||||
2016-12-01 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
J - Other | -1.500.000 | 6.013.134 | -19,97 | ||||
2016-11-30 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
J - Other | -58.950 | 121.153 | -32,73 | ||||
2016-11-30 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
J - Other | -2.941.050 | 10.834.849 | -21,35 | ||||
2016-11-25 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -290 | 180.103 | -0,16 | 9,39 | -2.722 | 1.690.609 | |
2016-11-25 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -14.451 | 13.775.899 | -0,10 | 9,39 | -135.650 | 129.312.986 | |
2016-11-25 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -248 | 180.393 | -0,14 | 9,30 | -2.307 | 1.678.340 | |
2016-11-25 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -12.352 | 13.790.350 | -0,09 | 9,30 | -114.921 | 128.302.658 | |
2016-11-25 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -189 | 180.641 | -0,10 | 9,33 | -1.763 | 1.685.326 | |
2016-11-25 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -9.411 | 13.802.702 | -0,07 | 9,33 | -87.802 | 128.775.069 | |
2016-11-21 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -2.327 | 180.830 | -1,27 | 9,39 | -21.841 | 1.697.270 | |
2016-11-21 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -116.058 | 13.812.113 | -0,83 | 9,39 | -1.089.320 | 129.640.493 | |
2016-11-21 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -1.976 | 183.157 | -1,07 | 9,47 | -18.720 | 1.735.156 | |
2016-11-21 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -98.586 | 13.928.171 | -0,70 | 9,47 | -933.964 | 131.949.921 | |
2016-11-21 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -6.389 | 185.133 | -3,34 | 9,64 | -61.612 | 1.785.312 | |
2016-11-21 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -318.764 | 14.026.757 | -2,22 | 9,64 | -3.073.969 | 135.265.628 | |
2016-11-17 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -342 | 191.522 | -0,18 | 9,51 | -3.252 | 1.821.125 | |
2016-11-17 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -17.052 | 14.345.521 | -0,12 | 9,51 | -162.142 | 136.407.256 | |
2016-11-17 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -3.094 | 191.864 | -1,59 | 9,55 | -29.558 | 1.832.954 | |
2016-11-17 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -154.359 | 14.362.573 | -1,06 | 9,55 | -1.474.653 | 137.211.405 | |
2016-08-17 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -633 | 2.042 | -23,66 | 136,45 | -86.373 | 278.631 | |
2016-08-15 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-Qualified Stock Option (right to buy) |
A - Award | 3.415 | 3.415 | |||||
2016-08-15 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 1.365 | 2.675 | 104,20 | ||||
2016-07-25 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Stock Option (Right to Buy) |
A - Award | 30.000 | 30.000 | |||||
2016-05-27 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 19.755 | 19.755 | |||||
2016-03-31 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 45.440 | 7.513.134 | 0,61 | 14,15 | 642.817 | 106.284.550 | |
2016-03-31 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 33.064 | 7.467.694 | 0,44 | 13,50 | 446.318 | 100.803.414 | |
2016-03-31 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 45.440 | 7.513.134 | 0,61 | 14,15 | 642.817 | 106.284.550 | |
2016-03-31 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 33.064 | 7.467.694 | 0,44 | 13,50 | 446.318 | 100.803.414 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -7 | 4.323 | -0,16 | 120,31 | -842 | 520.085 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -34 | 4.330 | -0,78 | 119,55 | -4.065 | 517.639 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -63 | 4.364 | -1,42 | 118,39 | -7.459 | 516.669 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -52 | 4.427 | -1,16 | 117,46 | -6.108 | 519.984 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -34 | 4.479 | -0,75 | 116,19 | -3.951 | 520.422 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -6 | 4.513 | -0,13 | 114,43 | -687 | 516.408 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -393 | 215.677 | -0,18 | 120,32 | -47.288 | 25.951.227 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1.666 | 216.070 | -0,77 | 119,55 | -199.165 | 25.830.542 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3.159 | 217.736 | -1,43 | 118,40 | -374.013 | 25.779.050 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2.594 | 220.895 | -1,16 | 117,46 | -304.692 | 25.946.415 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1.698 | 223.489 | -0,75 | 116,20 | -197.304 | 25.968.930 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -294 | 225.187 | -0,13 | 114,43 | -33.641 | 25.767.405 | |
2016-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -24 | 4.519 | -0,53 | 139,24 | -3.342 | 629.220 | |
2016-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -57 | 4.543 | -1,24 | 138,37 | -7.887 | 628.594 | |
2016-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -116 | 4.600 | -2,46 | 137,71 | -15.974 | 633.454 | |
2016-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1.214 | 225.481 | -0,54 | 139,24 | -169.043 | 31.397.034 | |
2016-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2.843 | 226.695 | -1,24 | 138,36 | -393.371 | 31.366.563 | |
2016-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -5.746 | 229.538 | -2,44 | 137,71 | -791.274 | 31.609.357 | |
2015-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -424 | 1.310 | -24,45 | 148,49 | -62.960 | 194.522 | |
2015-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -34 | 4.716 | -0,72 | 147,57 | -5.018 | 695.960 | |
2015-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -68 | 4.750 | -1,41 | 146,95 | -9.993 | 698.035 | |
2015-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -94 | 4.818 | -1,91 | 145,96 | -13.720 | 703.245 | |
2015-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1.737 | 235.284 | -0,73 | 147,58 | -256.339 | 34.722.225 | |
2015-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3.395 | 237.021 | -1,41 | 146,95 | -498.900 | 34.830.591 | |
2015-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -4.672 | 240.416 | -1,91 | 145,96 | -681.940 | 35.091.889 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -18 | 4.912 | -0,37 | 137,96 | -2.483 | 677.663 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -36 | 4.930 | -0,72 | 137,16 | -4.938 | 676.174 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -32 | 4.966 | -0,64 | 135,85 | -4.347 | 674.626 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -62 | 4.998 | -1,23 | 134,76 | -8.355 | 673.548 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -34 | 5.060 | -0,67 | 133,95 | -4.554 | 677.766 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -8 | 5.094 | -0,16 | 132,70 | -1.062 | 675.974 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -6 | 5.102 | -0,12 | 128,96 | -774 | 657.954 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -932 | 245.088 | -0,38 | 137,98 | -128.595 | 33.816.752 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1.809 | 246.020 | -0,73 | 137,15 | -248.097 | 33.740.634 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1.573 | 247.829 | -0,63 | 135,85 | -213.693 | 33.667.669 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3.138 | 249.402 | -1,24 | 134,76 | -422.878 | 33.609.463 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1.666 | 252.540 | -0,66 | 133,95 | -223.154 | 33.826.698 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -392 | 254.206 | -0,15 | 132,70 | -52.018 | 33.733.136 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -294 | 254.598 | -0,12 | 128,96 | -37.914 | 32.832.958 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1 | 5.108 | -0,02 | 137,81 | -138 | 703.933 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -34 | 5.109 | -0,66 | 136,60 | -4.645 | 697.910 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -10 | 5.143 | -0,19 | 135,73 | -1.357 | 698.039 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -25 | 5.153 | -0,48 | 134,32 | -3.358 | 692.137 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -83 | 5.178 | -1,58 | 132,94 | -11.034 | 688.358 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -43 | 5.261 | -0,81 | 132,26 | -5.687 | 695.799 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -99 | 254.892 | -0,04 | 137,81 | -13.643 | 35.126.667 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1.695 | 254.991 | -0,66 | 136,60 | -231.540 | 34.832.230 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -490 | 256.686 | -0,19 | 135,73 | -66.506 | 34.838.964 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1.225 | 257.176 | -0,47 | 134,32 | -164.539 | 34.543.160 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -4.193 | 258.401 | -1,60 | 132,94 | -557.414 | 34.351.622 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2.102 | 262.594 | -0,79 | 132,26 | -278.000 | 34.729.369 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -37 | 5.304 | -0,69 | 168,33 | -6.228 | 892.798 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -21 | 5.341 | -0,39 | 167,32 | -3.514 | 893.639 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -24 | 5.362 | -0,45 | 166,36 | -3.993 | 892.013 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -57 | 5.386 | -1,05 | 165,26 | -9.420 | 890.074 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -57 | 5.443 | -1,04 | 164,50 | -9.377 | 895.390 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1.857 | 264.696 | -0,70 | 168,34 | -312.602 | 44.558.210 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1.081 | 266.553 | -0,40 | 167,33 | -180.882 | 44.601.967 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1.169 | 267.634 | -0,43 | 166,36 | -194.472 | 44.522.843 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2.846 | 268.803 | -1,05 | 165,27 | -470.347 | 44.423.970 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2.851 | 271.649 | -1,04 | 164,51 | -469.018 | 44.688.977 | |
2015-08-31 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -425 | 1.734 | -19,69 | 167,87 | -71.345 | 291.087 | |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -21 | 5.500 | -0,38 | 183,75 | -3.859 | 1.010.625 |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -23 | 5.521 | -0,41 | 182,69 | -4.202 | 1.008.631 |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -148 | 5.544 | -2,60 | 181,71 | -26.893 | 1.007.400 |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -4 | 5.692 | -0,07 | 180,05 | -720 | 1.024.845 |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -1.069 | 274.500 | -0,39 | 183,77 | -196.450 | 50.444.865 |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -1.177 | 275.569 | -0,43 | 182,68 | -215.014 | 50.340.945 |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -7.362 | 276.746 | -2,59 | 181,71 | -1.337.749 | 50.287.516 |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -196 | 284.108 | -0,07 | 180,05 | -35.290 | 51.153.645 |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -4 | 2.159 | -0,18 | 183,36 | -733 | 395.874 | |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -797 | 2.163 | -26,93 | 179,98 | -143.444 | 389.297 | |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Nonstatutory Stock Option (right to buy) |
A - Award | 3.415 | 3.415 | |||||
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 1.310 | 2.960 | 79,39 | ||||
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -3.248.600 | 0 | -100,00 | ||||
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -3.873.530 | 0 | -100,00 | ||||
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 312.500 | 7.434.630 | 4,39 | 16,00 | 5.000.000 | 118.954.080 | |
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 3.248.600 | 7.122.130 | 83,87 | ||||
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 3.873.530 | 3.873.530 | |||||
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -3.248.600 | 0 | -100,00 | ||||
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -3.873.530 | 0 | -100,00 | ||||
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 312.500 | 7.434.630 | 4,39 | 16,00 | 5.000.000 | 118.954.080 | |
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 3.248.600 | 7.122.130 | 83,87 | ||||
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 3.873.530 | 3.873.530 | |||||
2015-07-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -10 | 5.696 | -0,18 | 178,59 | -1.786 | 1.017.254 | |
2015-07-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -60 | 5.706 | -1,04 | 177,74 | -10.665 | 1.014.196 | |
2015-07-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -105 | 5.766 | -1,79 | 176,86 | -18.570 | 1.019.761 | |
2015-07-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -22 | 5.871 | -0,37 | 175,81 | -3.868 | 1.032.165 | |
2015-07-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -543 | 284.304 | -0,19 | 178,59 | -96.977 | 50.775.017 | |
2015-07-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2.986 | 284.847 | -1,04 | 177,74 | -530.727 | 50.628.222 | |
2015-07-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -5.196 | 287.833 | -1,77 | 176,86 | -918.943 | 50.904.964 | |
2015-07-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1.078 | 293.029 | -0,37 | 175,81 | -189.520 | 51.516.637 | |
2015-06-22 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Stock Option (Right to Buy) |
A - Award | 30.000 | 30.000 | |||||
2015-06-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -47 | 5.893 | -0,79 | 179,43 | -8.433 | 1.057.379 | |
2015-06-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -109 | 5.940 | -1,80 | 178,76 | -19.485 | 1.061.831 | |
2015-06-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -40 | 6.049 | -0,66 | 177,82 | -7.113 | 1.075.614 | |
2015-06-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2.397 | 294.107 | -0,81 | 179,43 | -430.099 | 52.772.266 | |
2015-06-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -5.447 | 296.504 | -1,80 | 178,76 | -973.685 | 53.001.928 | |
2015-06-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1.960 | 301.951 | -0,64 | 177,82 | -348.521 | 53.691.961 | |
2015-05-18 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 8.000 | 8.000 | |||||
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Series D Convertible Preferred Stock |
C - Conversion | -101.128 | 0 | -100,00 | ||||
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Series D Convertible Preferred Stock |
C - Conversion | -5.045.381 | 0 | -100,00 | ||||
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Series C Convertible Preferred Stock |
C - Conversion | -63.356 | 0 | -100,00 | ||||
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Series C Convertible Preferred Stock |
C - Conversion | -3.160.905 | 0 | -100,00 | ||||
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Series B Convertible Preferred Stock |
C - Conversion | -257.303 | 0 | -100,00 | ||||
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Series B Convertible Preferred Stock |
C - Conversion | -12.837.935 | 0 | -100,00 | ||||
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Common Stock |
P - Purchase | 3.930 | 65.270 | 6,41 | 12,00 | 47.160 | 783.240 | |
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Common Stock |
C - Conversion | 61.340 | 61.340 | |||||
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Common Stock |
P - Purchase | 196.070 | 3.256.572 | 6,41 | 12,00 | 2.352.840 | 39.078.864 | |
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Common Stock |
C - Conversion | 3.060.502 | 3.060.502 | |||||
2015-05-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -60 | 6.089 | -0,98 | 176,63 | -10.598 | 1.075.517 | |
2015-05-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -137 | 6.149 | -2,18 | 175,98 | -24.109 | 1.082.073 | |
2015-05-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3.022 | 303.911 | -0,98 | 176,64 | -533.800 | 53.682.201 | |
2015-05-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -6.781 | 306.933 | -2,16 | 175,98 | -1.193.289 | 54.012.657 | |
2015-04-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -28 | 6.286 | -0,44 | 169,96 | -4.759 | 1.068.394 | |
2015-04-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -125 | 6.314 | -1,94 | 169,23 | -21.154 | 1.068.545 | |
2015-04-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -43 | 6.439 | -0,66 | 168,31 | -7.237 | 1.083.760 | |
2015-04-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1.402 | 313.714 | -0,44 | 169,97 | -238.301 | 53.322.753 | |
2015-04-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -6.275 | 315.116 | -1,95 | 169,24 | -1.061.958 | 53.329.097 | |
2015-04-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2.127 | 321.391 | -0,66 | 168,32 | -358.008 | 54.095.280 | |
2015-04-01 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Warrant (Right to Buy) |
X - Other | -16.833 | 0 | -100,00 | ||||
2015-04-01 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Warrant (Right to Buy) |
X - Other | -839.811 | 0 | -100,00 | ||||
2015-04-01 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
X - Other | 16.833 | 194.958 | 9,45 | 4,05 | 68.174 | 789.580 | |
2015-04-01 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
X - Other | 839.811 | 14.516.932 | 6,14 | 4,05 | 3.401.235 | 58.793.575 | |
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Warrant (Right to Buy) |
X - Other | -1.130.709 | 0 | -100,00 | ||||
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -554.348 | 13.677.121 | -3,90 | 5,65 | -3.132.066 | 77.275.734 | |
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
X - Other | 1.130.709 | 14.231.469 | 8,63 | 2,77 | 3.132.064 | 39.421.169 | |
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Warrant (Right to Buy) |
X - Other | -9.750 | 0 | -100,00 | ||||
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Warrant (Right to Buy) |
X - Other | -486.443 | 0 | -100,00 | ||||
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Warrant (Right to Buy) |
X - Other | -634.516 | 1.130.709 | -35,95 | ||||
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -4.617 | 178.125 | -2,53 | 5,85 | -27.009 | 1.042.031 | |
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
X - Other | 9.750 | 182.742 | 5,64 | 2,77 | 27.008 | 506.195 | |
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -230.333 | 13.100.760 | -1,73 | 5,85 | -1.347.448 | 76.639.446 | |
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
X - Other | 486.443 | 13.331.093 | 3,79 | 2,77 | 1.347.447 | 36.927.128 | |
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -300.447 | 12.844.650 | -2,29 | 5,85 | -1.757.615 | 75.141.202 | |
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
X - Other | 634.516 | 13.145.097 | 5,07 | 2,77 | 1.757.609 | 36.411.919 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -123 | 18.361 | -0,67 | 116,05 | -14.275 | 2.130.849 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -44 | 18.484 | -0,24 | 114,15 | -5.022 | 2.109.862 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -3.907 | 18.528 | -17,41 | 113,92 | -445.080 | 2.110.682 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -67 | 22.435 | -0,30 | 111,06 | -7.441 | 2.491.618 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -5.684 | 22.502 | -20,17 | 110,01 | -625.279 | 2.475.375 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -6.077 | 916.035 | -0,66 | 116,05 | -705.254 | 106.308.610 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -2.156 | 922.112 | -0,23 | 114,15 | -246.097 | 105.254.751 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -194.988 | 924.268 | -17,42 | 113,92 | -22.212.701 | 105.291.039 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -3.353 | 1.119.256 | -0,30 | 111,06 | -372.381 | 124.303.452 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -283.601 | 1.122.609 | -20,17 | 110,01 | -31.198.067 | 123.494.736 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3 | 6.482 | -0,05 | 177,51 | -533 | 1.150.620 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -87 | 6.485 | -1,32 | 176,79 | -15.381 | 1.146.501 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -57 | 6.572 | -0,86 | 176,03 | -10.033 | 1.156.838 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -38 | 6.629 | -0,57 | 175,06 | -6.652 | 1.160.498 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -12 | 6.667 | -0,18 | 172,60 | -2.071 | 1.150.713 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -197 | 323.518 | -0,06 | 177,51 | -34.969 | 57.427.680 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -4.302 | 323.715 | -1,31 | 176,79 | -760.560 | 57.230.319 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2.854 | 328.017 | -0,86 | 176,02 | -502.374 | 57.738.996 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1.862 | 330.871 | -0,56 | 175,06 | -325.969 | 57.923.535 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -588 | 332.733 | -0,18 | 172,60 | -101.488 | 57.429.150 | |
2015-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3 | 6.679 | -0,04 | 168,13 | -504 | 1.122.940 | |
2015-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -68 | 6.682 | -1,01 | 167,51 | -11.391 | 1.119.298 | |
2015-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -125 | 6.750 | -1,82 | 166,45 | -20.807 | 1.123.568 | |
2015-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -197 | 333.321 | -0,06 | 168,14 | -33.123 | 56.042.960 | |
2015-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3.382 | 333.518 | -1,00 | 167,51 | -566.507 | 55.866.400 | |
2015-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -6.225 | 336.900 | -1,81 | 166,46 | -1.036.187 | 56.078.925 | |
2015-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -9 | 6.875 | -0,13 | 161,54 | -1.454 | 1.110.588 | |
2015-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -88 | 6.884 | -1,26 | 160,75 | -14.146 | 1.106.600 | |
2015-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -100 | 6.972 | -1,41 | 159,68 | -15.968 | 1.113.262 | |
2015-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -495 | 343.125 | -0,14 | 161,57 | -79.975 | 55.437.368 | |
2015-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -4.348 | 343.620 | -1,25 | 160,75 | -698.938 | 55.236.709 | |
2015-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -4.960 | 347.968 | -1,41 | 159,68 | -792.002 | 55.562.765 | |
2014-12-16 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -300 | 1.650 | -15,38 | 172,53 | -51.759 | 284.674 | |
2014-12-16 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -650 | 1.950 | -25,00 | 171,67 | -111.588 | 334.765 | |
2014-12-16 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1.393 | 2.600 | -34,89 | 170,32 | -237.256 | 442.832 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -5 | 7.072 | -0,07 | 177,10 | -886 | 1.252.451 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -10 | 7.077 | -0,14 | 174,97 | -1.750 | 1.238.263 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -48 | 7.087 | -0,67 | 173,73 | -8.339 | 1.231.216 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -60 | 7.135 | -0,83 | 173,03 | -10.382 | 1.234.553 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -25 | 7.195 | -0,35 | 171,65 | -4.291 | 1.235.033 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -48 | 7.220 | -0,66 | 170,96 | -8.206 | 1.234.337 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -295 | 352.928 | -0,08 | 177,10 | -52.244 | 62.503.549 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -490 | 353.223 | -0,14 | 174,97 | -85.735 | 61.803.428 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2.403 | 353.713 | -0,67 | 173,73 | -417.466 | 61.449.569 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3.007 | 356.116 | -0,84 | 173,02 | -520.280 | 61.616.259 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1.208 | 359.123 | -0,34 | 171,65 | -207.349 | 61.642.314 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2.401 | 360.331 | -0,66 | 170,97 | -410.495 | 61.605.142 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -8 | 28.186 | -0,03 | 32,13 | -257 | 905.653 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -92 | 28.194 | -0,33 | 31,57 | -2.904 | 889.989 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -412 | 1.406.210 | -0,03 | 32,14 | -13.241 | 45.192.355 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -4.592 | 1.406.622 | -0,33 | 31,56 | -144.944 | 44.399.179 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -2.722 | 28.286 | -8,78 | 33,79 | -91.975 | 955.773 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -2.728 | 31.008 | -8,09 | 32,93 | -89.844 | 1.021.214 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -4.021 | 33.736 | -10,65 | 32,01 | -128.718 | 1.079.940 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -135.816 | 1.411.214 | -8,78 | 33,79 | -4.589.182 | 47.684.498 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -136.148 | 1.547.030 | -8,09 | 32,93 | -4.483.885 | 50.949.731 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -200.591 | 1.683.178 | -10,65 | 32,01 | -6.421.219 | 53.881.053 | |
2014-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -46 | 7.268 | -0,63 | 171,71 | -7.899 | 1.247.971 | |
2014-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -151 | 7.314 | -2,02 | 170,90 | -25.805 | 1.249.934 | |
2014-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2.258 | 362.732 | -0,62 | 171,71 | -387.716 | 62.283.841 | |
2014-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -7.545 | 364.990 | -2,03 | 170,90 | -1.289.438 | 62.376.682 | |
2014-10-14 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -19 | 37.757 | -0,05 | 30,00 | -570 | 1.132.710 | |
2014-10-14 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -924 | 1.883.769 | -0,05 | 30,00 | -27.720 | 56.513.070 | |
2014-10-09 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -235 | 37.776 | -0,62 | 30,04 | -7.059 | 1.134.802 | |
2014-10-09 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -11.692 | 1.884.693 | -0,62 | 30,04 | -351.230 | 56.616.555 | |
2014-10-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -43 | 7.465 | -0,57 | 161,57 | -6.947 | 1.206.085 | |
2014-10-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -104 | 7.508 | -1,37 | 160,65 | -16.708 | 1.206.165 | |
2014-10-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -49 | 7.612 | -0,64 | 159,47 | -7.814 | 1.213.914 | |
2014-10-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2.157 | 372.535 | -0,58 | 161,57 | -348.516 | 60.192.082 | |
2014-10-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -5.197 | 374.692 | -1,37 | 160,65 | -834.911 | 60.195.169 | |
2014-10-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2.450 | 379.889 | -0,64 | 159,48 | -390.738 | 60.586.559 | |
2014-09-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -38 | 7.661 | -0,49 | 163,88 | -6.227 | 1.255.464 | |
2014-09-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -159 | 7.699 | -2,02 | 162,71 | -25.871 | 1.252.690 | |
2014-09-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1.909 | 382.339 | -0,50 | 163,89 | -312.865 | 62.661.386 | |
2014-09-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -7.894 | 384.248 | -2,01 | 162,71 | -1.284.424 | 62.520.569 | |
2014-08-14 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1.087 | 3.993 | -21,40 | 133,15 | -144.734 | 531.668 | |
2014-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Nonstatutory Stock Option (right to buy) |
A - Award | 3.300 | 3.300 | |||||
2014-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 1.650 | 5.080 | 48,10 | ||||
2014-05-16 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 5.000 | 5.000 | |||||
2014-05-12 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Stock Options (right to buy) |
A - Award | 30.000 | 30.000 | |||||
2014-05-05 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -1.699 | 172.992 | -0,97 | 4,07 | -6.918 | 704.389 | |
2014-05-05 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -84.744 | 12.510.581 | -0,67 | 4,07 | -345.061 | 50.940.584 | |
2014-05-05 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -3.214 | 174.691 | -1,81 | 4,12 | -13.256 | 720.513 | |
2014-05-05 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -160.343 | 12.595.325 | -1,26 | 4,12 | -661.335 | 51.949.418 | |
2014-04-03 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -4.912 | 177.905 | -2,69 | 4,28 | -21.035 | 761.843 | |
2014-04-03 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -245.088 | 12.755.668 | -1,89 | 4,28 | -1.049.540 | 54.623.597 | |
2014-03-07 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -205 | 182.817 | -0,11 | 4,00 | -820 | 731.268 | |
2014-03-07 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -10.225 | 13.000.756 | -0,08 | 4,00 | -40.900 | 52.003.024 | |
2014-03-07 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -3.303 | 183.022 | -1,77 | 4,00 | -13.214 | 732.216 | |
2014-03-07 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -164.800 | 13.010.981 | -1,25 | 4,00 | -659.315 | 52.053.032 | |
2014-03-07 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -1.404 | 186.325 | -0,75 | 4,01 | -5.630 | 747.126 | |
2014-03-07 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -70.063 | 13.175.781 | -0,53 | 4,01 | -280.939 | 52.832.247 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3.895 | 0 | -100,00 | 153,80 | -599.043 | ||
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1.166 | 3.895 | -23,04 | 150,45 | -175.429 | 586.017 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3.700 | 5.061 | -42,23 | 149,42 | -552.855 | 756.216 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2.700 | 8.761 | -23,56 | 148,55 | -401.088 | 1.301.456 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -300 | 11.461 | -2,55 | 147,87 | -44.360 | 1.694.700 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Warrant (right to buy) |
X - Other | -18.624 | 0 | -100,00 | ||||
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Warrant (right to buy) |
X - Other | -929.243 | 0 | -100,00 | ||||
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -8.731 | 7.858 | -52,63 | 150,50 | -1.314.016 | 1.182.629 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -435.588 | 392.142 | -52,62 | 150,50 | -65.555.994 | 59.017.371 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -559 | 16.589 | -3,26 | 159,03 | -88.897 | 2.638.127 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -28.070 | 827.730 | -3,28 | 159,03 | -4.463.927 | 131.632.578 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -423 | 17.148 | -2,41 | 159,91 | -67.642 | 2.742.121 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -20.977 | 855.800 | -2,39 | 159,91 | -3.354.449 | 136.851.663 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -180 | 17.571 | -1,01 | 160,77 | -28.939 | 2.824.944 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -8.866 | 876.777 | -1,00 | 160,76 | -1.425.330 | 140.953.827 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -787 | 17.751 | -4,25 | 161,93 | -127.442 | 2.874.492 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -39.241 | 885.643 | -4,24 | 161,93 | -6.354.448 | 143.415.625 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -71 | 18.538 | -0,38 | 162,94 | -11.569 | 3.020.574 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3.645 | 924.884 | -0,39 | 162,94 | -593.906 | 150.698.102 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1 | 18.609 | -0,01 | 164,50 | -164 | 3.061.180 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -28 | 928.529 | 0,00 | 164,50 | -4.606 | 152.743.020 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -14 | 18.610 | -0,08 | 165,94 | -2.323 | 3.088.143 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -686 | 928.557 | -0,07 | 165,94 | -113.835 | 154.084.749 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
X - Other | 18.624 | 18.624 | 4,00 | 74.496 | 74.496 | ||
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
X - Other | 929.243 | 929.243 | 4,00 | 3.716.972 | 3.716.972 | ||
2013-08-14 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1.070 | 3.430 | -23,78 | 81,86 | -87.590 | 280.780 | |
2013-08-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Nonstatutory Stock Option (right to buy) |
A - Award | 4.500 | 4.500 | |||||
2013-08-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 2.250 | 4.500 | 100,00 | ||||
2013-07-01 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 21.471 | 21.471 | |||||
2013-07-01 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -33.753 | 0 | -100,00 | ||||
2013-07-01 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -1.683.967 | 0 | -100,00 | ||||
2013-07-01 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
P - Purchase | 4.258 | 38.011 | 12,62 | 14,00 | 59.612 | 532.154 | |
2013-07-01 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
P - Purchase | 212.418 | 1.896.385 | 12,61 | 14,00 | 2.973.852 | 26.549.390 | |
2013-07-01 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
C - Conversion | 33.753 | 33.753 | |||||
2013-07-01 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
C - Conversion | 1.683.967 | 1.683.967 | |||||
2013-05-21 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Stock Options (right to buy) |
A - Award | 30.000 | 30.000 | |||||
2013-03-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -15.720 | 15.422 | -50,48 | 58,28 | -916.162 | 898.794 | |
2013-03-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -784.280 | 768.670 | -50,50 | 58,28 | -45.707.838 | 44.798.088 | |
2013-02-20 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -921 | 31.142 | -2,87 | 58,13 | -53.536 | 1.810.228 |
2013-02-20 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -46.451 | 1.552.950 | -2,90 | 58,13 | -2.700.085 | 90.269.256 |
2013-02-20 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -4 | 32.063 | -0,01 | 59,04 | -236 | 1.893.000 |
2013-02-20 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -375 | 32.067 | -1,16 | 58,41 | -21.905 | 1.873.110 |
2013-02-20 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -196 | 1.599.401 | -0,01 | 59,04 | -11.572 | 94.428.635 |
2013-02-20 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -18.703 | 1.599.597 | -1,16 | 58,41 | -1.092.476 | 93.435.340 |
2013-01-16 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -456 | 32.442 | -1,39 | 56,72 | -25.865 | 1.840.159 |
2013-01-16 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -22.772 | 1.618.300 | -1,39 | 56,72 | -1.291.669 | 91.792.889 |
2013-01-14 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -31 | 32.898 | -0,09 | 56,54 | -1.753 | 1.860.033 |
2013-01-14 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -1.569 | 1.641.072 | -0,10 | 56,54 | -88.710 | 92.785.226 |
2013-01-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -706 | 32.929 | -2,10 | 56,52 | -39.906 | 1.861.299 |
2013-01-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -35.216 | 1.642.641 | -2,10 | 56,52 | -1.990.563 | 92.849.297 |
2013-01-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -117 | 33.635 | -0,35 | 56,52 | -6.612 | 1.900.932 |
2013-01-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -5.783 | 1.677.857 | -0,34 | 56,52 | -326.834 | 94.826.437 |
2012-10-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -72 | 33.752 | -0,21 | 59,34 | -4.273 | 2.002.877 |
2012-10-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -1.228 | 33.824 | -3,50 | 58,59 | -71.946 | 1.981.681 |
2012-10-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -3.667 | 1.683.640 | -0,22 | 59,34 | -217.607 | 99.910.565 |
2012-10-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -61.683 | 1.687.307 | -3,53 | 58,59 | -3.613.884 | 98.855.943 |
2012-08-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Option (right to buy) |
A - Award | 4.500 | 4.500 | |||||
2012-08-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 2.250 | 2.250 | |||||
2012-06-15 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Stock Options (right to buy) |
A - Award | 30.000 | 30.000 | |||||
2012-04-02 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Warrants (Right to Buy) |
P - Purchase | 856.644 | 856.644 | 0,12 | 107.080 | 107.080 | ||
2012-04-02 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Warrants (Right to Buy) |
X - Other | -856.644 | 0 | -100,00 | 0,12 | -107.080 | ||
2012-04-02 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
X - Other | 856.644 | 13.433.573 | 6,81 | 2,96 | 2.535.666 | 39.763.376 | |
2012-03-09 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -21.615 | 35.052 | -38,14 | 49,56 | -1.071.239 | 1.737.177 | |
2012-03-09 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1.078.400 | 1.748.990 | -38,14 | 49,56 | -53.445.504 | 86.679.944 | |
2012-03-09 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -49.985 | 0 | -100,00 | 49,56 | -2.477.257 | ||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Warrant (right to buy) |
A - Award | 18.624 | 18.624 | |||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Warrant (right to buy) |
A - Award | 929.243 | 929.243 | |||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Phantom Stock |
A - Award | 9.929 | 9.929 | |||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 56.667 | 56.667 | |||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 2.827.390 | 2.827.390 | |||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 49.985 | 49.985 | |||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Warrant (right to buy) |
D - Sale to Issuer | -18.624 | 0 | -100,00 | ||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Warrant (right to buy) |
D - Sale to Issuer | -929.243 | 0 | -100,00 | ||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Phantom Stock |
D - Sale to Issuer | -9.929 | 0 | -100,00 | ||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Common Stock |
D - Sale to Issuer | -56.667 | 0 | -100,00 | ||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Common Stock |
D - Sale to Issuer | -2.827.390 | 0 | -100,00 | ||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Common Stock |
D - Sale to Issuer | -49.985 | 0 | -100,00 | ||||
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Option (right to buy) |
M - Exercise | -12.500 | 0 | -100,00 | ||||
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Option (right to buy) |
M - Exercise | -12.500 | 0 | -100,00 | ||||
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Option (right to buy) |
M - Exercise | -10.000 | 0 | -100,00 | ||||
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Option (right to buy) |
M - Exercise | -30.000 | 0 | -100,00 | ||||
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Common Stock |
F - Taxes | -8.999 | 49.985 | -15,26 | 48,60 | -437.351 | 2.429.271 | |
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Common Stock |
M - Exercise | 12.500 | 58.984 | 26,89 | 34,99 | 437.375 | 2.063.850 | |
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Common Stock |
F - Taxes | -2.116 | 46.484 | -4,35 | 48,60 | -102.838 | 2.259.122 | |
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Common Stock |
M - Exercise | 12.500 | 48.600 | 34,63 | 8,23 | 102.875 | 399.978 | |
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Common Stock |
F - Taxes | -1.302 | 36.100 | -3,48 | 48,60 | -63.277 | 1.754.460 | |
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Common Stock |
M - Exercise | 10.000 | 37.402 | 36,49 | 6,33 | 63.300 | 236.755 | |
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Common Stock |
F - Taxes | -2.598 | 27.402 | -8,66 | 48,60 | -126.263 | 1.331.737 | |
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Common Stock |
M - Exercise | 30.000 | 30.000 | 4,21 | 126.300 | 126.300 |